	US 12,466,838 B2
	Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
Franck Raeppel, Montreal (CA); and Stephane L. Raeppel, Boucherville (CA)
Assigned to MIRATI THERAPEUTICS, INC., Princeton, NJ (US)
Appl. No. 17/762,713
Filed by Mirati Therapeutics, Inc., San Diego, CA (US)
PCT Filed Sep. 9, 2020, PCT No. PCT/US2020/049986 § 371(c)(1), (2) Date Mar. 22, 2022, PCT Pub. No. WO2021/050580, PCT Pub. Date Mar. 18, 2021.
Claims priority of provisional application 62/898,469, filed on Sep. 10, 2019.
Prior Publication US 2022/0402936 A1, Dec. 22, 2022
Int. Cl. C07D 495/04 (2006.01); A61P 35/00 (2006.01)

CPC C07D 495/04 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)]

31 Claims

1. A crystalline form of N-(3-fluoro-4-((2-(5-(((2-methoxyethyl) amino) methyl) pyridin-2-yl)thieno[3,2-b]pyridin-7-yl) oxy) phenyl)-N-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide.